Diflunisal 250 MG Oral Tablet [Dolobid] — RxCUI 105823
RxNorm drug concept · Semantic branded drug
RxCUI 105823
Semantic branded drug · SBD
● Current RxNorm concept 2 FDA products
2 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI105823
Official nameDiflunisal 250 MG Oral Tablet [Dolobid]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asDolobid 250 MG Oral Tablet
FDA products mapped2
Package NDCs mapped2
Reported Medicaid activity (SDUD)18,146 prescriptions · 3 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Diflunisal: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Diflunisal is an anti-inflammatory pain reliever — an NSAID — used to treat mild to moderate pain and to help manage the symptoms of osteoarthritis and rheumatoid arthritis. It can...
- Swallow the tablets whole — don't crush or chew them. For pain, you'll usually take a higher first dose to get things working, then a lower dose every 8 to 12 hours after that. For...
- The most common ones are stomach-related — nausea, stomach pain, diarrhea, and sometimes constipation. You might also notice headache, dizziness, or ringing in your ears. Most of t...
- What side effects should I watch out for?
🕸️ Concept Web — How Diflunisal 250 MG Oral Tablet [Dolobid] Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Diflunisal 250 MG Oral Tablet [Dolobid]
RxCUI 105823 Semantic branded drug · SBD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Diflunisal
3393IN
-
Diflunisal
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Dolobid
202486BN
-
Dolobid
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Diflunisal Oral Tablet
371828SCDF -
Diflunisal Oral Product
1151511SCDG -
Diflunisal Pill
1151512SCDG -
Diflunisal Oral Tablet [Dolobid]
369174SBDF -
Dolobid Oral Product
1174563SBDG -
Dolobid Pill
1174564SBDG -
Oral Tablet
317541DF -
Oral Product
1151131DFG - +1 more in this family
-
Diflunisal Oral Tablet
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Diflunisal 250 MG Oral Tablet
197602SCD -
Diflunisal 250 MG
317354SCDC -
Diflunisal 250 MG [Dolobid]
564179SBDC
-
Diflunisal 250 MG Oral Tablet
Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Diflunisal 250 MG Oral Tablet
SCD · 197602 -
Diflunisal 250 MG
SCDC · 317354 -
Diflunisal Oral Tablet
SCDF · 371828 -
Diflunisal Oral Product
SCDG · 1151511 -
Diflunisal Pill
SCDG · 1151512
Brand-Name Concepts
-
Diflunisal 250 MG [Dolobid]
SBDC · 564179 -
Diflunisal Oral Tablet [Dolobid]
SBDF · 369174 -
Dolobid Oral Product
SBDG · 1174563 -
Dolobid Pill
SBDG · 1174564 -
Dolobid
BN · 202486
📦 FDA Products & Package NDCs
2 products · 2 package NDCs
2 package NDCs map to RxCUI 105823 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 74157-0009-60 | 60 TABLET, FILM COATED in 1 BOTTLE (74157-009-60) | Dolobid | INA Pharmaceutics Inc | 2024-08-19 |
| 74157-0101-60 | 60 TABLET, FILM COATED in 1 BOTTLE (74157-101-60) | Dolobid | INA Pharmaceutics Inc | 2024-08-19 |
Observed labelers:
INA Pharmaceutics Inc (2)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.